CVS and Novo Nordisk have struck a deal that will see the drugstore chain offering the Wegovy weight-loss drug to customers at a discount.
Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket. That’s the same rate Novo Nordisk has offered previously through its online pharmacy.
The company also raised its 2025 guidance to a range of $6 to $6.20 in earnings per share, up from $5.75 to $6.
